| Identification | More | [Name]
OLSALAZINE | [CAS]
15722-48-2 | [Synonyms]
OLSALAZINE
3,3’-azobis(6-hydroxy-benzoicaci
3,3’-azobis(6-hydroxybenzoicacid)
5,5’-azobis(salicylicacid)
azodisal
c.i.mordantyellow5
Ph-CJ-91B
4,4'-Dihydroxyazobenzene-3,3'-dicarboxylic acid
5,5'-Azodisalicylic acid | [EINECS(EC#)]
605-089-5 | [Molecular Formula]
C14H10N2O6 | [MDL Number]
MFCD00602469 | [Molecular Weight]
302.24 | [MOL File]
15722-48-2.mol |
| Chemical Properties | Back Directory | [Melting point ]
>300 °C(Solv: acetic acid (64-19-7); water (7732-18-5)) | [Boiling point ]
443.29°C (rough estimate) | [density ]
1.3578 (rough estimate) | [refractive index ]
1.6500 (estimate) | [solubility ]
DMSO: soluble
Methanol: soluble | [form ]
Solid | [pka]
2.40±0.10(Predicted) | [color ]
Light yellow to yellow | [Water Solubility ]
11.49ug/L(25 ºC) | [CAS DataBase Reference]
15722-48-2(CAS DataBase Reference) |
| Hazard Information | Back Directory | [Uses]
Anti-inflammatory (gastrointestinal). | [Definition]
ChEBI: An azobenzene that consists of two molecules of 4-aminosalicylic acid joined by an azo linkage. A prodrug for mesalazine, an anti-inflammatory drug, it is used (as the disodium salt) in the treatment of inflammatory bowel disease. | [Indications]
Olsalazine is approved for maintenance of remission
of ulcerative colitis, but a commonly reported
side effect is a paradoxical increase in diarrhea. The
U. S. Food and Drug Administration (FDA) has approved
balsalazide disodium (Colazal) as a treatment of
mild to moderately active ulcerative colitis. | [Brand name]
Dipentum (UCB). | [Mechanism of action]
Olsalazine is approved for maintenance of remission
of ulcerative colitis, but a commonly reported
side effect is a paradoxical increase in diarrhea. The
U. S. Food and Drug Administration (FDA) has approved
balsalazide disodium (Colazal) as a treatment of
mild to moderately active ulcerative colitis. | [Veterinary Drugs and Treatments]
Olsalazine is used for treatment of dogs with chronic colitis that either
cannot tolerate the adverse effects associated with sulfasalazine
or the response to sulfasalazine has been ineffective. | [References]
[1] S. NUGENT. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs[J]. Gut, 2001, 48 1: 571-577. DOI: 10.1136/gut.48.4.571
[2] R. PAMUKCU E C S Hanauer. Effect of disodium azodisalicylate on electrolyte transport in rabbit ileum and colon in vitro. Comparison with sulfasalazine and 5-aminosalicylic acid.[J]. Gastroenterology, 1988, 95 4 1: 975-981. DOI: 10.5555/uri:pii:0016508588901722
[3] A Q MOHSEN. Effects of olsalazine in the jejunum of the rat.[J]. Gut, 1987, 28 3: 346-352. DOI: 10.1136/gut.28.3.346
[4] S MURTHY. The efficacy of BAY y 1015 in dextran sulfate model of mouse colitis.[J]. Inflammation Research, 1997, 46 6: 224-233. DOI: 10.1007/s000110050177
[5] YANFEN NIU . Old drug, new indication: Olsalazine sodium reduced serum uric acid levels in mice via inhibiting xanthine oxidoreductase activity[J]. Journal of pharmacological sciences, 2017, 135 3: Pages 114-120. DOI: 10.1016/j.jphs.2017.10.007 |
|
|